XML 53 R38.htm IDEA: XBRL DOCUMENT v3.19.1
Quarterly Financial Information (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]  
Schedule of quarterly financial information (unaudited)
The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2018 and 2017 (unaudited):
 
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
December 31,
2018
 
September 30,
2018
 
June 30,
2018
 
March 31,
2018
Consolidated Statements of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
Revenue under collaborative research and development arrangements
$
2,372,600

 
$
1,813,287

 
$
24,385,852

 
$
1,289,046

Revenue under collaborative research and development arrangements with affiliated entity
56,207

 
184,990

 
60,319

 
148,008

Grants and miscellaneous revenue
73,817

 
2,591

 
2,590

 
92,590

Total revenues
2,502,624

 
2,000,868

 
24,448,761

 
1,529,644

Operating Expenses:
 
 
 
 
 
 
 
Research and development
26,365,647

 
21,851,858

 
22,462,620

 
24,577,751

General and administrative
5,636,141

 
6,791,693

 
7,189,310

 
9,698,015

Total operating expenses
32,001,788

 
28,643,551

 
29,651,930

 
34,275,766

Loss from operations
(29,499,164
)
 
(26,642,683
)
 
(5,203,169
)
 
(32,746,122
)
Interest and other income, net
(169,300
)
 
380,987

 
396,681

 
312,523

Change in fair value of common stock warrants
—

 
228,665

 
259,971

 
(127,841
)
Gain (loss) from investment in affiliated entity
(3,293,741
)
 
1,017,359

 
(2,092,608
)
 
2,380,423

Net loss before provision for income taxes
$
(32,962,205
)
 
$
(25,015,672
)
 
$
(6,639,125
)
 
$
(30,181,017
)
Provision for income taxes
—

 
—

 
—

 
(2,169,811
)
Net loss
$
(32,962,205
)
 
$
(25,015,672
)
 
$
(6,639,125
)
 
$
(32,350,828
)
Net loss per share
 
 
 
 
 
 
 
Basic
$
(0.34
)
 
$
(0.27
)
 
$
(0.07
)
 
$
(0.36
)
Diluted
$
(0.34
)
 
$
(0.27
)
 
$
(0.08
)
 
$
(0.36
)


 
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
Quarter Ended
 
December 31,
2017
 
September 30,
2017
 
June 30,
2017
 
March 31,
2017
Consolidated Statements of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
Revenue under collaborative research and development arrangements
$
7,409,214

 
$
351,272

 
$
16,358,316

 
$
4,288,586

Revenue under collaborative research and development arrangements with affiliated entity
226,486

 
129,133

 
176,879

 
233,330

Grants and miscellaneous revenue
980,443

 
1,456,216

 
2,797,647

 
5,240,233

Grants and miscellaneous revenue from affiliated entity
171,091

 
707,922

 
1,079,282

 
614,036

Total revenues
8,787,234

 
2,644,543

 
20,412,124

 
10,376,185

Operating Expenses:
 
 
 
 
 
 
 
Research and development
24,641,124

 
25,510,239

 
23,878,751

 
24,542,504

General and administrative
8,033,899

 
6,319,775

 
6,169,106

 
7,767,589

Gain on sale of assets
(1,000,000
)
 
—

 
—

 
—

Total operating expenses
31,675,023

 
31,830,014

 
30,047,857

 
32,310,093

Loss from operations
(22,887,789
)
 
(29,185,471
)
 
(9,635,733
)
 
(21,933,908
)
Interest and other income, net
509,266

 
463,346

 
300,021

 
340,341

Change in fair value of common stock warrants
579,546

 
423,296

 
(312,500
)
 
116,477

Gain (loss) from investment in affiliated entity
292,798

 
(5,835,741
)
 
169,096

 
(1,608,817
)
Net loss
$
(21,506,179
)
 
$
(34,134,570
)
 
$
(9,479,116
)
 
$
(23,085,907
)
Net loss per share
 
 
 
 
 
 
 
          Basic
$
(0.24
)
 
$
(0.39
)
 
$
(0.13
)
 
$
(0.31
)
          Diluted
$
(0.24
)
 
$
(0.40
)
 
$
(0.13
)
 
$
(0.31
)